SCHEMBL21685653

SCHEMBL21685653

CC(C)(C)OC(=O)N1C2CCC1CN(c1cc(F)c3c(c1)CCC(NC(=O)OCc1ccccc1)C3)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
ACHE P22303 2/20 0.47
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40
KMT2A Q03164 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RORC P51449 2/20 0.39
GPR119 Q8TDV5 2/20 0.39
SCN9A Q15858 1/20 0.39
MEN1 O00255 2/20 0.39
GPR55 Q9Y2T6 2/20 0.39
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
NTSR1 P30989 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30968493 1.00 CA1 (0.47) CA1CA2ACHECTSLCTSB
SCHEMBL30968530 0.88 CA1 (0.45) CA1CA2ACHECTSLCTSB
SCHEMBL20722621 0.87 CA1 (0.48) CA1CA2ACHECTSLCTSB
SCHEMBL28576430 0.87 CA1 (0.48) CA1CA2ACHECTSLCTSB
SCHEMBL30059971 0.87 CA1 (0.49) CA1CA2ACHECTSLCTSB
SCHEMBL20722755 0.87 CA1 (0.49) CA1CA2ACHECTSLCTSB
SCHEMBL24730159 0.87 KMT2A (0.39) CA1CA2ACHECTSLCTSB
SCHEMBL21685850 0.87 KMT2A (0.39) CA1CA2ACHECTSLCTSB
SCHEMBL20722616 0.87 KMT2A (0.39) CA1CA2ACHECTSLCTSB
SCHEMBL30061785 0.87 KMT2A (0.39) CA1CA2ACHECTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
EP-3833661-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Valo Early Discovery, Inc. (US) 2021-06-16 EP disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 CA1 1259/4885CA2 2429/4885ACHE 1811/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 CA1 1259/4885CA2 2429/4885ACHE 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.